Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB-656933 in Ulcerative Colitis
NCT00748410Phase 2Terminated
- Sponsor
- GSK
- Start
- Jan 2009
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of elubrixin in ulcerative colitis (UC), sponsored by GSK. Primary endpoint: Change From Baseline in 99m-Tc-HMPAO Leukocyte SPECT Scintigraphic Activity Scores at Day 7. Started Jan 2009; status: terminated.
02
Drugs
elubrixin
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT00748410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00748410.